Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of RAY1225 in Hepatic Impairment
NCT06577415Phase 1Recruiting
- Sponsor
- Raynovent Biotech
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of RAY1225 in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Raynovent Biotech. Primary endpoints: Area Under The Drug Concentration-Time Curve From Zero To Infinity and Maximum Observed Drug Concentration. Started Aug 2024; status: recruiting.
02
Drugs
RAY1225
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06577415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577415.